An experimental pill from Viking Therapeutics (VKTX) reduced liver fat in patients with early signs of fatty liver disease, according to results from a mid-stage clinical trial announced Tuesday.
The promising clinical trial results thrust Viking into the mix of companies racing to develop new treatments for NASH, the commonly used acronym for non-alcoholic steatohepatitis, a chronic disease in which fat accumulates in the liver.
About the Author Reprints
